Answers are grounded in this paper and cite their sources.
Participants using Technosphere Insulin experienced clinically non-inferior glycaemic control and lower hypoglycaemia rates across a range of HbA1c levels compared with participants receiving insulin aspart. ClinicalTrials.gov: NCT01445951.
No takes yet. Share an insight, caveat, or question.
Seaquist et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: